- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
IS LOW DOSE ALTEPLASE A VIABLE OPTION FOR ACUTE ISCHEMIC STROKE IN DEVELOPING COUNTRIES ? (GALLERY) - Nov 7, 2022 - Abstract #WSC2022WSC_1499;
Lower dose of alteplase was found to be non-inferior to standard dose of alteplase in terms of efficacy for thrombolysis in acute ischemic stroke. Symptomatic ICH is more common in thrombolysis with standard dose of alteplase and significantly less with low dose of alteplase.
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
SYSTEMIC HYPOPERFUSION ISCHEMIC STROKE PRESENTING WITH CONSIOUSNESS FLUCTUATION: A CASE REPORT (GALLERY) - Nov 7, 2022 - Abstract #WSC2022WSC_1456;
Acute ischemic stroke due to diminished blood flow can occur in patients with hypotension and present with consciouness fluctuation. Pulmonary embolism is a cause to look for, especially in patients with risk factors for thromboembolism.
- |||||||||| nerinetide (NA 1) / NoNO, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
ASSOCIATION OF CORTICAL AND SUBCORTICAL BRAIN ATROPHY WITH FUNCTIONAL OUTCOME AFTER EVT: GOING BEYOND CHRONOLOGICAL AGE (GALLERY) - Nov 7, 2022 - Abstract #WSC2022WSC_1274;
Adjustments were made for age, sex, final infarct volume (FIV), laterality, white matter hyperintensity burden, Nerinetide-Alteplase interaction, and study site. Brain atrophy is associated with less favorable outcome over time, in AIS patients treated with EVT within 12-hours of symptom onset.
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Clinical, Retrospective data, Journal: Hidden Telltale Signs in Hyperacute Ischemic Stroke Caused by Aortic Dissection: A Case Report and Post Hoc Analysis. (Pubmed Central) - Nov 5, 2022
Hyperacute ischemic stroke caused by AD often hides some telltale signs. Clinicians should master basic clinical skills to exclude AD by looking for these telltale signs hidden in hyperacute ischemic stroke to avoid the fatal consequences of intravenous thrombolysis and/or cerebral angiography within the narrow window of time.
- |||||||||| gruticibart (AB023) / Bayer, Aronora, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Factor XI Inhibition for the Prevention of Catheter-Associated Thrombosis in Cancer Patients Undergoing Central Line Placement: A Phase 2 Clinical Trial (291-292 (Ernest N. Morial Convention Center)) - Nov 4, 2022 - Abstract #ASH2022ASH_3522;
Nine patients in the interventional cohort received AB023, 8 of which underwent surveillance ultrasound, and 10 patients in the control cohort underwent surveillance ultrasound (Table 2). Malignancies included pancreatic cancer (4/11), colorectal cancer (3/11), and lymphoma (2/11) in the interventional study, and lymphoma (4/11) colorectal cancer (3/11), and head and neck cancer (3/11) in the control study.
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal, HEOR: Patient-Reported Quality of Life After Intravenous Alteplase for Stroke in the WAKE-UP Trial. (Pubmed Central) - Oct 29, 2022
SIRI and IPI can be a novel the good short-term prognostic biomarker for AIS patients treated with intravenous thrombolysis. Assessment of patient-reported outcome measures reveals a potential benefit of intravenous alteplase for HRQoL beyond improvement of functional outcome.
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Observational data, Retrospective data, Journal: Thrombolysis in central retinal artery occlusion: a retrospective observational study. (Pubmed Central) - Oct 29, 2022
Patients with NA-CRAO are at very high risk of ischemic stroke and MRI should be done in all patients for optimized treatment and secondary stroke prevention. A prospective randomized study is required.
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Review, Journal: A Review on Therapeutic Potential of Natural Phytocompounds for Stroke. (Pubmed Central) - Oct 29, 2022
In this review, we discuss some promising phytocompounds, such as flavone C-glycoside (apigenin-8-C-β-D-glucopyranoside), eriodictyol, rosamirinic acid, 6″-O-succinylapigenin, and allicin, that show effectiveness against stroke. Future study paths are given, as well as suggestions for expanding the use of medicinal plants and their formulations for stroke prevention.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: Tenecteplase versus alteplase for early treatment of ischaemic stroke. (Pubmed Central) - Oct 28, 2022
Future study paths are given, as well as suggestions for expanding the use of medicinal plants and their formulations for stroke prevention. No abstract available
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Enrollment open, Trial completion date, Trial primary completion date: STRATIFY: Low Dose Thrombolysis, Ultrasound Assisted Thrombolysis or Heparin for Intermediate High Risk Pulmonary Embolism (clinicaltrials.gov) - Oct 26, 2022
P3, N=210, Recruiting,
ANN NEUROL 2022;92:860-870. Unknown status --> Recruiting | Trial completion date: Oct 2021 --> Oct 2023 | Trial primary completion date: Jun 2021 --> Jun 2023
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: Early effect of thrombolysis on structural brain network organisation after anterior-circulation stroke in the randomized WAKE-UP trial. (Pubmed Central) - Oct 22, 2022
We present a secondary analysis of 269 patients from the randomized WAKE-UP trial, comparing 127 imaging-selected patients treated with alteplase with 142 controls who received placebo...This interplay between the location of the lesion, the pathophysiology of the ischemic penumbra, and the spatial embedding of the brain network explains the observed potential of thrombolysis to attenuate topological network damage early after stroke. Our findings might, in the future, lead to new brain network-informed imaging biomarkers and improved prognostication in ischemic stroke.
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: A Case-Control Study of Distinguishing Between Stroke Mimics and True Strokes. (Pubmed Central) - Oct 21, 2022
We conducted a retrospective case-control study on 116 adult patients who received alteplase (tPA) to treat acute stroke at our hospital...We could potentially avoid the administration of tPA to such patients, reducing both the cost and adverse effects of it. Every stroke can cause neurological deficits, but every deficit need not be a stroke.
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: Tissue plasminogen activator in left ventricular assist device-related intravascular hemolysis after failed augmented anticoagulation. (Pubmed Central) - Oct 20, 2022
We sought to examine the efficacy and safety of adding fibrinogen-guided low-dose multi-day Alteplase™ tissue plasminogen activator (tPA) in the management of intravascular hemolysis (IVH) in patients with the HeartMate II (HM-II) continuous flow (CF) left ventricular assist device (LVAD) who failed to achieve IVH resolution with conventional augmented anticoagulation (AAC)...Ischemic CVA occurred in 6/31 (19.4%) patients. Management of IVH with administration of low-dose tPA after failed AAC is feasible and may prevent pump exchange in some patients.
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Clinical, Journal: Catheter-Directed Thrombolysis vs Anticoagulation in Patients With Acute Intermediate-High-risk Pulmonary Embolism: The CANARY Randomized Clinical Trial. (Pubmed Central) - Oct 20, 2022
P3
Patients were randomly assigned to cCDT (alteplase, 0.5 mg/catheter/h for 24 hours) plus heparin vs anticoagulation monotherapy...This prematurely terminated randomized clinical trial of patients with intermediate-high-risk PE was hypothesis-generating for improvement in some efficacy outcomes and acceptable rate of major bleeding for cCDT compared with anticoagulation monotherapy and provided support for a definitive clinical outcomes trial. ClinicalTrials.gov Identifier: NCT05172115.
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Review, Journal: Intravenous thrombolysis in CADASIL: report of two cases and a systematic review. (Pubmed Central) - Oct 19, 2022
ClinicalTrials.gov Identifier: NCT05172115. Available data on intravenous thrombolysis in CADASIL patients are scarce but suggest that this treatment can be taken into consideration for these patients.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Journal: The promise of tenecteplase in acute stroke: Within reach or beyond approval? (Pubmed Central) - Oct 19, 2022
Increasing evidence supports tenecteplase as an alternative to alteplase, with many potential benefits. This article discusses the current state of the evidence for intravenous reperfusion and considers strategies for improving access, including possible modifications to efficacy-related regulatory updates.
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Enrollment open, Trial completion date, Trial primary completion date: CRAD-001-03: A Study of r-PA Treating Patients With Acute Ischemic Stroke?RAISE? (clinicaltrials.gov) - Oct 17, 2022
P3, N=1412, Recruiting,
He presented only with acute severe dyspnea followed by cardiac arrest. Not yet recruiting --> Recruiting | Trial completion date: Mar 2025 --> May 2023 | Trial primary completion date: Mar 2024 --> May 2023
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Thrombotic Thrombocytopenia With Acute Graft Thrombosis (AGT) After Kidney Transplantation () - Oct 15, 2022 - Abstract #KIDNEYWEEK2022KIDNEY_WEEK_4473;
Graft was removed, flushed with heparin/alteplase and reimplanted with doppler-confirmed BF...Following resolved thrombocytopenia and negative PF-4 Ab, she had a second LUKT on therapeutic argatroban...Like HIT, VITT is thought to be from IgG binding to the PF-4-heparin complex, activating platelets and initiating a hypercoagulable cascade with platelet consumption. Although clinically similar, HIT and VITT are treated differently, thus it is vital to differentiate the two.
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Review, Journal: Neuronal Death Mechanisms and Therapeutic Strategy in Ischemic Stroke. (Pubmed Central) - Oct 14, 2022
Current relatively effective clinical treatments are limited to intravenous alteplase and thrombectomy...Thus, in this article, we first review the principal mechanisms underlying neuronal death mediated by these significant events, such as intrinsic and extrinsic apoptosis, ferroptosis, parthanatos, pyroptosis, necroptosis, and autophagic cell death. Then, we further discuss the possibility of interventions targeting these pathological events and summarize the present pharmacological achievements.
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Use of Alteplase in Long-Term Catheters Causes Hyperphosphataemia in Children on Hemodialysis (Exhibit Hall, Orange County Convention Center, West Building) - Oct 13, 2022 - Abstract #KIDNEYWEEK2022KIDNEY_WEEK_1300;
Conclusion Alteplase has phosphoric acid in its composition, and use in catheters may distort the phosphataemia of patients depending on the site of sample collection. Patients with a long-stay catheter in the use of alteplase should analyze the serum P after the withdrawal of the connector, aspiration of the lumen volume and prefilter collection after the onset of hemodialysis, under risk of false diagnosis of hyperphosphatemia and introduction of unnecessary treatments.
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Safety and Practical Use of 4% Tetrasodium EDTA for Pediatric Hemodialysis (HD) Line Locking (Exhibit Hall, Orange County Convention Center, West Building) - Oct 13, 2022 - Abstract #KIDNEYWEEK2022KIDNEY_WEEK_1299;
Unlike standard locking solutions (e.g., heparin and alteplase), 4% tetrasodium EDTA (Kitelock™) has antimicrobial and antibiofilm properties...However, significant chelation was seen on labs drawn from the CVL after small-volume discards, necessitating a change in sampling protocol. Further data is needed to evaluate if 4% tetrasodium EDTA can reduce CLABSI risk.
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Clinical data, Retrospective data, Review, Journal: Prevalence, risk factors, and clinical outcomes of remote intracerebral hemorrhage after intravenous thrombolysis in acute ischemic stroke: a systematic review and meta-analysis. (Pubmed Central) - Oct 7, 2022
Although rICH is uncommon after intravenous thrombolysis, its presence can lead to worse functional outcomes and higher mortality in acute ischemic stroke. Patients at high risk of rICH must be identified based on potential risk factors.
|
